SCNI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Scinai Immunotherapeutics Ltd (SCNI) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 to invest. The stock lacks clear positive trading signals, has weak financial performance, and no significant catalysts to drive immediate growth. It is best to hold off on investing until more favorable conditions or signals emerge.
The MACD is slightly positive but contracting, RSI is neutral at 39.49, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 0.855, with support at 0.714 and resistance at 0.996.
The company has submitted a revised application for a €12 million grant to support its R&D program for PC111, which could advance clinical development and improve financial flexibility if approved.
The company's financial performance is weak, with a net income loss of -$2.23 million in Q4 2024 and a 100% YoY drop in EPS. Additionally, the grant decision is months away, offering no immediate impact.
In Q4 2024, revenue remained stagnant at $206,000 (0% YoY growth), while net income dropped to -$2.23 million (-4.29% YoY). EPS fell to 0, down 100% YoY, and gross margin remained negative at -164.29%.
No recent analyst ratings or price target changes are available for SCNI.
